Established in 1993 and previously led by Dr. Beryl Koblin, the Laboratory of Infectious Disease Prevention is a leader in HIV and infectious disease epidemiology and prevention research. We are part of the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide (NIH/NIAID-funded HIV Vaccine Trials Network, www.hvtn.org).
As part of the global response to the COVID-19 pandemic caused by SARS-CoV-2 virus, we are also part of the clinical trials program devoted to the development and testing of SARS-CoV-2 vaccines and monoclonal antibodies to prevent COVID-19 (NIH/NIAID-funded COVID-19 Prevention Network, www.coronaviruspreventionnetwork.org).
We use epidemiology to stay up to date on who is at risk for HIV and other infectious diseases and why. We design and test innovative prevention strategies to increase HIV testing and pre-exposure prophylaxis (PrEP) uptake and reduce risk. We conduct our epidemiology and clinical studies and community engagement through our research site, Project ACHIEVE (www.projectachieve.org).
Our research collaborators include the Columbia Research Unit. Together, we form the NIH-funded by Columbia Collaborative HIV/AIDS Clinical Trials Unit.
HIV Vaccine and Monoclonal Antibody Studies
In collaboration with the HIV Vaccine Trials Network (HVTN) and Columbia Collaborative HIV/AIDS Clinical Trials Unit, our research involves implementation of multiple Phase 1-3 clinical research trials to test the safety, tolerability, and efficacy of HIV vaccine products and monoclonal antibodies to prevent HIV infection.
HIV Long-Acting Pre-Exposure Prophylaxis Study
In collaboration with the HIV Prevention Trials Network (HPTN), this multi-site, multi-country HPTN 083 study is a Phase 2b/3 study comparing long-acting cabotegravir to oral daily emtricitabine/tenofovir (FTC/TDF) for preventing HIV infection in men who have sex with men and transgender women.
SARS-CoV-2 Vaccine and Treatment Studies
In collaboration with the COVID-19 Prevention Network (CoVPN), our research involves implementation of multiple Phase 3 SARS-CoV-2 clinical research trials to test the safety, tolerability, and efficacy of vaccine products to prevent COVID-19, as well as a study testing whether vaccination with the Moderna mRNA vaccine reduces infection and spread of SARS-CoV-2 virus to close contacts.
We also are involved in the SCORPIO-HR ACTIV-2D/A5407 trial, a Phase 3 multicenter, randomized trial testing the antiviral effect of S-217622, an oral SARS-CoV-2 3CL protease inhibitor, compared with placebo in non-hospitalized adults with COVID-19.
Neighborhoods, Networks, and the HIV Care Continuum
The NNHIV study is an NIH/NIMH- R56 and R01-funded three-phase research study that involves a mixed methods approach to ascertain neighborhood and network factors that influence HIV care continuum outcomes (retention in care, antiretroviral therapy adherence, and viral suppression) among men who have sex with men living with HIV in New York City using qualitative interviews, spatial analysis and multilevel modeling. This is followed by a longitudinal study among 327 MSM living with HIV over two years to evaluate the influence of neighborhoods and networks on HIV care continuum over time.
The Envio study is an NIH/NIMH R21-funded study among 50 young Black and Latinx MSM living with HIV to characterize the spaces where they experience violence and to assess the impact of these experiences on HIV care outcomes over time and space and contextualize these impacts.
- NIH/NIMH R21 MH124474-01 (Tieu/Frye), 07/2020 – 06/2023, Mixed Methods Study Evaluating Violence and HIV Care and Viral Suppression
- NIH R01 MH118960 (Tieu), 05/2019 – 02/2023 Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC
- NIH UM1 AI068614-14S1 (Corey, subcontract to Tieu), 08/2020 – 02/2023, COVID-19 Prevention Trials Network for Phase 3 COVID-19 Vaccine and Monoclonal Antibody Trials
- UM1 AI068619 (Cohen, subcontract to Tieu), 1/2017 – 12/2022, HIV Prevention Trials Network (HPTN) 083
- NIH 2UM1 AI069470 (Sobieszczyk, subcontract to Tieu), 12/2020 – 11/2027, Columbia Collaborative HIV/AIDS Clinical Trials Unit (2UM1AI069470-15) Research Grant; NIH 2UM1 AI0569470 (Hammer/El-Sadr, subcontract to Tieu), 12/2013 – 11/2020, Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit
Education and Training
BS, Economics, Wharton School, University of Pennsylvania
MD, Mount Sinai School of Medicine
MS, Epidemiology, Columbia University Mailman School of Public Health
Internal medicine residency, Department of Medicine, Boston University Medical Center
Infectious diseases fellowship, Division of Infectious Diseases/Department of Medicine, Columbia University Medical Center
Infectious disease epidemiology research fellowship, Center for Infectious Disease Epidemiologic Research, Columbia University Mailman School of Public Health
Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, Neuzil KM, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022 Sep 15;132(18):e160565. doi: 10.1172/JCI160565.
Rael CT, Pierre D, Frye V, Kessler D, Duffy L, Malos N, Tieu HV. Evaluating blood donor experiences and barriers/facilitators to blood donation in the United States using YouTube video content. Transfusion 2021. doi: 10.1111/trf.16568.
Teitelman AM, Koblin BA, Brawner BM, Davis A, Darlington C, Lipsky RK, Iwu E, Bond KT, Westover J, Fiore D, Tieu HV. Just4Us: Development of a Counselor-Navigator and Text Message Intervention to Promote PrEP Uptake Among Cisgender Women at Elevated Risk for HIV. J Assoc Nurses AIDS Care 2021. doi: 10.1097/JNC.0000000000000233.
Teitelman AM, Chittamuru D, Koblin BA, Davis A, Brawner BM, Fiore D, Broomes T, Ortiz G, Lucy D, Tieu HV. Beliefs Associated with Intention to Use PrEP Among Cisgender U.S. Women at Elevated HIV Risk. Arch Sex Behav 2020;49(6):2213-2221. doi:10.1007/s10508-020-01681-3.
Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, Baden LR, Valencia J, Sobieszczyk M, Tieu HV, Allen M, Hural J, Graham BS, Kublin J, Gilbert PB, Corey L, Goepfert PA, McElrath MJ, Johnson RP, Huang Y, Frahm N. Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Sci Transl Med 2019;11(519). pii: eaaw1673. doi: 10.1126/scitranslmed.aaw1673.
Hermanstyne KA, Green HD Jr, Tieu HV, Hucks-Ortiz C, Wilton L, Shoptaw S. The Association Between Condomless Anal Sex and Social Support Among Black Men Who Have Sex With Men (MSM) in Six U.S. Cities: A Study Using Data from the HIV Prevention Trials Network BROTHERS Study (HPTN 061). AIDS Behav 2018; doi: 10.1007/s10461-018-2315-y.
Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Tieu HV, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC2; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network. PLoS Med 2017;14(11):e1002435. doi:10.1371/journal.pmed.1002435.
Markowitz M, Frank I, Grant RM, Mayer KM, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Tieu HV, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart, AR, Smith KY. Spreen W. ECLAIR: a randomised phase IIa safety and pharmacokinetic study of cabotegravir long-1 acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet Infectious Diseases 2017;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1.
Tieu HV, Nandi V, Hoover DR, Lucy D, Stewart K, Frye V, Cerda M, Ompad D, Latkin C, Koblin BA on behalf of the NYC M2M Study Team. Do Sexual Networks of Men Who Have Sex with Men in New York City Differ by Race/Ethnicity? AIDS Patient Care and STDs 2016: 30(1):39-47. doi:10.1089/apc.2015.0237.
Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061. Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS ONE 2015: 10(8):e0134085. doi: 10.1371/journal.pone.0134085.
Tieu HV, Nandi V, Frye V, Stewart K, Oquendo H, Bush B, Cerda M, Hoover DR, Ompad D, Koblin BA. Concurrent Partnerships and HIV Risk among Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2014:41(3):200-8.
Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013;64(1):121-125.